Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

第4相 完了 NCT03963375

概要

The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple sclerosis (RMS; to include relapsing-remitting MS \[RRMS\] or active secondary progressive MS).

Change in CD3+ T Cells % From Baseline to Week 5

Baseline to Week 5 (5 weeks after first cladribine dose) · Percentage of CD3+ T cells

Change in CD3+ T Cells % From Baseline to Week 10

Baseline to Week 10 (10 weeks after first cladribine dose) · Percentage of CD3+ T cells

Change in CD3+ T Cells % From Baseline to Year 1

Baseline to Year 1 (45 weeks after first cladribine dose) · Percentage of CD3+ T cells

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of — Mapi Pharma Ltd.
• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
• A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
• Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral — Shionogi

すべての治験